CIPSM spin-off XL-protein with its revolutionary PASylation technology has been awarded the Science4Life Venture Cup 2010 for its excellent business concept for the development of novel biologics with prolonged action. XL-biologics, a spin-off of XL-protein, will focus on the development of superior biopharmaceuticals with extended plasma half-life utilising the PASylation technology. Uli Binder, CTO of XL-protein, states: “We are very happy that our concept was so highly valued in this well reputed competition. This reassures our efforts to apply the ‘PASylation’ technology in order to help patients to improve their quality of life.” At the final stage of the contest XL-biologics successfully competed with business concepts by 54 teams mainly from the areas of biotechnology, pharmaceuticals and medical engineering. The Science4Life Venture Cup is the key business plan contest in Germany for life sciences and chemistry, co-sponsored by the states government of Hesse and Sanofi-Aventis.